

DAFTAR PUSTAKA

1. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al.. Management of malignant pleural effusions. *Eur Respir J*. 2001 Aug;18(2):402–19.
2. Perhimpunan Dokter Paru Indonesia. *Kanker Paru, Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta: Balai Penerbit FKUI; 2005.
3. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. *Eur Respir Rev an Off J Eur Respir Soc*. 2016 Jun;25(140):189–98.
4. Tian P, Qiu R, Wang M, Xu S, Cao L, Yang P, et al.. Prevalence, Causes, and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China. *JAMA Netw open*. 2021 Aug;4(8):e2120306.
5. Sakti BT, Rosalina R, Pradipta J. Characteristics of Pleural Effusion in Patients with Cancer at the Dharmais Cancer Hospital Emergency Room. *Indones J Cancer*; Vol 15, No 4 December [Internet]. 2021; Available from: <https://www.indonesianjournalofcancer.or.id/ejournal/index.php/ijoc/article/view/835>
6. DeBiasi EM, Pisani MA, Murphy TE, Araujo K, Kookoolis A, Argento AC, et al.. Mortality among patients with pleural effusion undergoing thoracentesis. *Eur Respir J* [Internet]. 2015 Aug 1;46(2):495 LP – 502. Available from: <http://erj.ersjournals.com/content/46/2/495.abstract>
7. Boka K. Pleural Effusion. *Medscape*. 2021.
8. Krishna R, Antoine MH, Rudrappa M. Pleural Effusion. In *Treasure Island (FL)*; 2023.
9. Sidiq MF, Agustina H KI. Profil klinis, gambaran makroskopis dan mikroskopis cairan efusi pleura pada pasien rawat inap di departemen ilmu penyakit dalam RSUP Dr . Hasan Sadikin Bandung periode Januari 2016 - Desember 2018. *Indones J Chest*. 2020;7(1):1–10.
10. Shafiq M, Ma X, Taghizadeh N, Kharrazi H, Feller-Kopman DJ, Tremblay A, et al.. Healthcare Costs and Utilization among Patients Hospitalized for Malignant Pleural Effusion. *Respiration* [Internet]. 2020;99(3):257–63.

Available from: <https://www.karger.com/DOI/10.1159/000506210>

11. Taghizadeh N, Fortin M, Tremblay A. US Hospitalizations for Malignant Pleural Effusions: Data From the 2012 National Inpatient Sample. *Chest* [Internet]. 2017;151(4):845–54. Available from: <https://www.sciencedirect.com/science/article/pii/S0012369216623577>
12. Quek JC, Tan QL, Allen JC, Anantham D. Malignant pleural effusion survival prognostication in an Asian population. *Respirology*. 2020 Dec;25(12):1283–91.
13. Gayaf M, Anar C, Canbaz M, Doğan Bİ, Erbaycu AE, Güldaval F. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion? *Tuberk Toraks*. 2021 Jun;69(2):133–43.
14. Arora RD, Boster J. Malignant Pleural Effusion. In *Treasure Island (FL)*; 2023.
15. Napitupulu E, Soeroso NN, Tarigan SP, Eyoer PC. Respiratory Emergency in Hospitalized patient with Intrathoracic Malignancy at H. Adam Malik General Hospital. *J Respirologi Indones* Vol 42, No 1 [Internet]. 2022; Available from: <http://jurnalrespirologi.org/index.php/jri/article/view/12>
16. Verma A, Phua C, Sim W, Algozo R, Tee K, Lew S, et al.. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion. *Medicine (Baltimore)*. 2016 Jun 1;95:e3996.
17. Han YQ, Zhang L, Yan L, Ouyang PH, Li P, Hu ZD. Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis. *Ann Transl Med*. 2019 Oct;7(20):554.
18. Zamboni MM, da Silva CTJ, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. *BMC Pulm Med*. 2015 Mar;15:29.
19. Popowicz N, Cheah HM, Gregory C, Miranda A, Dick IM, Lee YCG, et al.. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. *PLoS One*. 2021;16(4):e0250628.
20. Lim JU, Yeo CD, Kim HW, Kang HS, Park CK, Kim JS, et al.. Pleural

Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer. *In Vivo*. 2020;34(4):2179–85.

21. Ermin S, Özdoğan Y, Batum Ö, Yilmaz U. The role of LENT and PROMISE scores in predicting survival in malignant pleural effusion. *Lung India*. 2022;39(4):325–30.
22. Peng P, Yang Y, Du J, Zhai K, Shi HZ. Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis. *Cancer Cell Int*. 2022 Feb;22(1):99.
23. Cortés-Telles A, Formento-Ceballos F, Vargas G. Performance of LENT Score in Hispanic Population with Malignant Pleural Effusion. *Glob J Respir Care*. 2020 Sep 25;6:16–21.
24. Skok K, Hladnik G, Grm A, Crnjac A. Malignant Pleural Effusion and Its Current Management: A Review. *Medicina (Kaunas)*. 2019 Aug;55(8).
25. Jovanovic D. Etiopathogenesis of malignant pleural effusion. *AME Med Journal*; Vol 6 (September 25, 2021) *AME Med J [Internet]*. 2020; Available from: <https://amj.amegroups.com/article/view/5951>
26. Devi YG, Koyyana P, Nookaraju V, Padmaja B, Mounika P AP. Role of LENT Score in Prognosis of Malignant Pleural Effusions. *Indian J Respir Care*. 2022;11(2):106–11.
27. Dermawan JKT, Policarpio-Nicolas ML. Malignancies in Pleural, Peritoneal, and Pericardial Effusions. *Arch Pathol Lab Med*. 2020 Sep;144(9):1086–91.
28. Chollet B, Guinde J, Laroumagne S, Dutau H, Astoul P. Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study. *Thorac cancer*. 2021 Jun;12(11):1752–6.
29. Ernawati Y, Ermayanti S, Herman D, Russilawati R. Faktor Risiko Kanker Paru pada Perempuan yang Dirawat di Bagian Paru RSUP Dr. M. Djamil Padang dan RSUD Solok: Penelitian Case Control. *J Kesehat Andalas*. 2019;8(2):1–7.
30. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.. Cancer incidence and mortality worldwide: Sources, methods and major

- patterns in GLOBOCAN 2012. *Int J Cancer* [Internet]. 2015 Mar 1;136(5):E359–86. Available from: <https://doi.org/10.1002/ijc.29210>
31. Murata EP, Bielsa S, Pardina M, Salud Salvia A, Porcel L, Porcel J. Impact of pleural effusion in ovarian cancer: A retrospective study in Lleida, Spain. *J Clin Oncol* [Internet]. 2021 May 20;39(15_suppl):e17534–e17534. Available from: https://doi.org/10.1200/JCO.2021.39.15_suppl.e17534
 32. Kim CH, Oh HG, Lee SY, Lim JK, Lee YH, Seo H, et al.. Differential diagnosis between lymphoma-associated malignant pleural effusion and tuberculous pleural effusion. *Ann Transl Med*. 2019;7 16:373.
 33. Subotic D. Malignant pleural effusion and mesothelioma. *AME Med Journal*; Vol 5 (March 2020) *AME Med J* [Internet]. 2020; Available from: <https://amj.amegroups.com/article/view/5427>
 34. Dixit R, Agarwal KC, Gokhroo A, Patil CB, Meena M, Shah NS, et al.. Diagnosis and management options in malignant pleural effusions. *Lung India*. 2017;34(2):160–6.
 35. Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I. Management of malignant pleural effusion: Challenges and solutions. *Cancer Manag Res*. 2017;9:229–41.
 36. Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). *Mol Med Rep*. 2018 Jun;17(6):8019–30.
 37. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al.. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. *Thorax*. 2014 Dec;69(12):1098–104.
 38. Abisheganaden J, Verma A, Dagaonkar RS, Light RW. An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore. *Respiration*. 2018;96(4):308–13.
 39. Shehata SM, Sileem AE, El-Fakharany KM. Pleural fluid CRP, LDH, and pH as predictors of successful pleurodesis in malignant pleural effusions. *Egypt J Chest Dis Tuberc* [Internet]. 2015;64(3):593–9. Available from:

<https://www.sciencedirect.com/science/article/pii/S0422763815201203>

40. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor. *Brain Pathol.* 2016 Jan;26(1):3–17.
41. Mishra D, Banerjee D. Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment. *Cancers (Basel).* 2019 May;11(6).
42. Rawat D, Chhonker SK, Naik RA, Mehrotra A, Trigun SK, Koiri RK. Lactate as a signaling molecule: Journey from dead end product of glycolysis to tumor survival. *Front Biosci (Landmark Ed.* 2019 Jan;24(2):366–81.
43. Azam F, Latif MF, Farooq A, Tirmazy SH, Alshahrani S, Bashir S, et al.. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. *Case Rep Oncol.* 2019;12(3):728–36.
44. Faria SS, Fernandes PCJ, Silva MJB, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: a narrative review. *Ecancermedicalsecience.* 2016;10:702.
45. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. *Int J Mol Sci.* 2022 Mar;23(7).
46. Lee YS, Nam HS, Lim JH, Kim JS, Moon Y, Cho JH, et al.. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients. *BMC Cancer.* 2017 Aug;17(1):557.
47. Lee PY, Oen KQX, Lim GRS, Hartono JL, Muthiah M, Huang DQ, et al.. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. *Cancers (Basel).* 2021 Mar;13(6).
48. Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. *Nat Rev Cancer [Internet].* 2020;20(9):485–503. Available from: <https://doi.org/10.1038/s41568-020-0281-y>

49. Raimundo S, Loureiro AI, Vieira F, Fernandes A. LENT Score: Predicting the Survival of Malignant Pleural Effusion - A Prospective Study of Three Years. Vol. 56, Archivos de bronconeumologia. Spain; 2020. p. 465–6.
50. Gutman SI, Piper M, Grant MD, Basch E, Oliansky DM, Aronson N. Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? Agency Healthc Res Qual. 2013 Apr;
51. Sousa S, Caldeira JN, Figueiredo A, Barata F. LENT score in prognostic assessment of malignant pleural effusion – the impact of target therapy. Rev do Grup Estud do Cancro do Pulmão. 2021;
52. Akram MJ, Khalid U, Ashraf MB, Bakar MA, Butt FM, Khan F. Predicting the survival in patients with malignant pleural effusion undergoing indwelling pleural catheter insertion. Ann Thorac Med. 2020;15(4):223–9.
53. Markatis E, Perlepe G, Afthinos A, Pagkratis K, Varsamas C, Chaini E, et al.. Mortality Among Hospitalized Patients With Pleural Effusions. A Multicenter, Observational, Prospective Study. Front Med. 2022;9:828783.
54. Hassan M, Mercer RM, Maskell NA, Asciak R, McCracken DJ, Bedawi EO, et al.. Survival in patients with malignant pleural effusion undergoing talc pleurodesis. Lung Cancer [Internet]. 2019;137:14–8. Available from: <https://www.sciencedirect.com/science/article/pii/S0169500219306361>
55. Basso Smm, Lumachi F, Conte Adel, Sulfaro S, Maffeis F, Ubiali P. Diagnosis of Malignant Pleural Effusion Using CT Scan and Pleural-Fluid Cytology Together. A Preliminary Case–Control Study. Anticancer Res [Internet]. 2020 Feb 1;40(2):1135 LPN – 1139. Available from: <http://ar.iiarjournals.org/content/40/2/1135.abstract>
56. Piskac Zivkovic N, Cikara I, Novak NP, Brkljacic B, Tudoric N. A Retrospective Study of Ultrasound Characteristics and Macroscopic Findings in Confirmed Malignant Pleural Effusion. Pulm Med.2019;2019:5628267.
57. Wu SG, Liu YN, Yu CJ, Yang JCH, Shih JY. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosom Cancer. 2018;57(10):513–21.
58. Zhang X, Yi FS, Shi HZ. Predicting Survival for Patients with Malignant Pleural Effusion: Development of the CONCH Prognostic Model. Cancer Manag Res [Internet]. 2021 Dec 31;13:4699–707. Available from:

- <https://www.tandfonline.com/doi/abs/10.2147/CMAR.S305223>
59. Ramesh S, Hazarika B, Sarma J, Karwa R. Etiology and prognostic evaluation of malignant pleural effusion. *Int J Community Med Public Heal* [Internet]. 2020 Mar 26;7(4 SE-Original Research Articles):1405–9. Available from: <https://www.ijcmph.com/index.php/ijcmph/article/view/5958>
 60. Taniguchi Y, Tamiya A, Isa SI, Nakahama K, Okishio K, Shiroyama T, et al.. Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab. *Anticancer Res*. 2017 Oct;37(10):5857–62.
 61. Tang H, Ma H, Peng F, Bao Y, Hu X, Wang J, et al.. Prognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapy. *Mol Clin Oncol*. 2016 May;4(5):801–6.
 62. Caldeira J, et al.. 20 Years Managing Malignant Pleural Mesothelioma: a Review of Our Experience and the Quest for the Optimal Prognostic Marker. *Rev do Grup Estud do Cancro do Pulmão*. 2022;18(2):9–17.
 63. Karkhanis V, Joshi J. Pleural effusion: diagnosis, treatment, and management. *Open Access Emerg Med*. 2012 Jun;31.
 64. Crooks, V, Waller S, et al. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. *J Gerontol*. 1991; 46:M139-144.
 65. Ocagli. H, Cella. N, Stivanello. L , Degan. M , Canova. C. ‘The Barthel index as an indicator of hospital outcomes: A retrospective cross-sectional study with healthcare data from older people’, *Journal of Advanced Nursing*. 2020;77: 44.
 66. The International Agency for Research on Cancer. GLOBOCAN 2020. Geneva: IARC;2020.